All FDA-approved peptide and peptide-based therapeutics as of 2026. Includes native peptide hormones, analogs, and peptide-conjugate drugs.
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Insulin (regular) | 1982 | T1D, T2D | INSR agonist | Various | SC, IV |
| Insulin lispro (Humalog) | 1996 | T1D, T2D | Rapid-acting INSR agonist | Eli Lilly | SC |
| Insulin aspart (NovoLog) | 2000 | T1D, T2D | Rapid-acting INSR agonist | Novo Nordisk | SC |
| Insulin glargine (Lantus) | 2000 | T1D, T2D | Long-acting INSR agonist | Sanofi | SC |
| Insulin detemir (Levemir) | 2005 | T1D, T2D | Long-acting INSR agonist | Novo Nordisk | SC |
| Exenatide (Byetta) | 2005 | T2D | GLP-1R agonist | AstraZeneca | SC BID |
| Liraglutide (Victoza) | 2010 | T2D | GLP-1R agonist | Novo Nordisk | SC daily |
| Insulin degludec (Tresiba) | 2013 | T1D, T2D | Ultra-long INSR agonist | Novo Nordisk | SC |
| Dulaglutide (Trulicity) | 2014 | T2D | GLP-1R agonist (Fc-fusion) | Eli Lilly | SC weekly |
| Exenatide ER (Bydureon) | 2014 | T2D | GLP-1R agonist (microsphere) | AstraZeneca | SC weekly |
| Semaglutide (Ozempic) | 2017 | T2D | GLP-1R agonist | Novo Nordisk | SC weekly |
| Semaglutide oral (Rybelsus) | 2019 | T2D | GLP-1R agonist (oral) | Novo Nordisk | Oral daily |
| Tirzepatide (Mounjaro) | 2022 | T2D | Dual GLP-1R/GIPR agonist | Eli Lilly | SC weekly |
| Semaglutide 2.4 mg (Wegovy) | 2021 | Obesity | GLP-1R agonist (dose escalation) | Novo Nordisk | SC weekly |
| Tirzepatide (Zepbound) | 2023 | Obesity | Dual GLP-1R/GIPR agonist | Eli Lilly | SC weekly |
| Pramlintide (Symlin) | 2005 | T1D, T2D (adjunct) | Amylin analog | AstraZeneca | SC |
| Setmelanotide (Imcivree) | 2020 | Obesity (POMC, PCSK1, LEPR deficiency) | MC4R agonist | Rhythm Pharma | SC daily |
| Insulin icodec (Awiqli) | 2023 | T1D, T2D | Ultra-long INSR agonist (weekly) | Novo Nordisk | SC weekly |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Leuprolide (Lupron) | 1985 | Prostate cancer | GnRH agonist | AbbVie | SC, IM |
| Goserelin (Zoladex) | 1989 | Prostate/breast cancer | GnRH agonist | AstraZeneca | SC implant |
| Buserelin (Suprefact) | 1988 | Prostate cancer | GnRH agonist | Sanofi-Aventis | SC, IM |
| Triptorelin (Trelstar) | 2000 | Prostate cancer | GnRH agonist | Debiopharm | IM |
| Nafarelin (Synarel) | 1990 | Endometriosis, precocious puberty | GnRH agonist | Pfizer | Intranasal |
| Histrelin (Vantas) | 2004 | Prostate cancer | GnRH agonist (implant) | Endo Pharma | SC implant |
| Octreotide (Sandostatin) | 1988 | Acromegaly, NETs | Somatostatin analog | Novartis | SC, IM |
| Lanreotide (Somatuline) | 2007 | NETs, acromegaly | Somatostatin analog | Ipsen | SC |
| Pasireotide (Signifor) | 2012 | Cushing’s disease | Somatostatin analog (multi-SSTR) | Novartis | SC |
| Lutetium-177 DOTATATE (Lutathera) | 2018 | NETs | SSTR-targeted radioligand | Novartis | IV |
| Carfilzomib (Kyprolis) | 2012 | Multiple myeloma | Proteasome inhibitor | Amgen | IV |
| Bortezomib (Velcade) | 2003 | Multiple myeloma, MCL | Proteasome inhibitor | Janssen | IV, SC |
| Carmustine (BiCNU) | 1977 | Brain tumors, NHL, HL | Alkylating agent | Emc Pharma | IV |
| Melphalan (Alkeran) | 1953 | Multiple myeloma | Alkylating agent | GlaxoSmithKline | IV, PO |
| L-Asparaginase (Elspar) | 1978 | ALL | Asparagine depletion | Various | IV, IM |
| Mipsagargin (G-202) | Investigational | HCC, GBM | PSMA-targeted | Gennova | IV |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Oxytocin (Pitocin) | 1955 | Labor induction, PPH | OTR agonist | Various | SC, IV |
| Desmopressin (DDAVP) | 1978 | Diabetes insipidus, nocturia | V2R agonist | Sanofi-Aventis | SC, IV, Intranasal |
| Oxytocin nasal (Syntocinon) | 2018 | Lactation support | OTR agonist | Various | Intranasal |
| Bremelanotide (Vyleesi) | 2019 | FSD (premenopausal) | MC4R agonist | Palatin Tech | SC PRN |
| Alprostadil (Caverject) | 1983 | ED | PGE₁ (vasodilator) | Pfizer | ICI |
| Alprostadil (Muse) | 1996 | ED | PGE₁ (urethral) | Meda Pharma | Urethral |
| Terlipressin (Galphis) | 2022 | Hepatorenal syndrome | V1aR agonist | Mallinckrodt | IV |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Teriparatide (Forteo) | 2002 | Osteoporosis | PTH 1-34 analog | Eli Lilly | SC |
| Abaloparatide (Tymlos) | 2017 | Osteoporosis | PTHrP analog | Radius Health | SC |
| Calcitonin (Miacalcin) | 1986 | Paget’s, osteoporosis | Calcitonin analog | Various | SC, Intranasal |
| Etelcalcetide (Parsabiv) | 2017 | SHPT (CKD) | Calcimimetic (peptide) | Amgen | IV |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Nesiritide (Natrecor) | 2001 | Acute decompensated HF | BNP analog (vasodilator) | Scios | IV |
| Carperitide | 1995 (Japan) | Acute HF | ANP analog | Nichi-Iko | IV |
| Bivalirudin (Angiomax) | 2000 | ACS, PCI | Direct thrombin inhibitor | The Medicines Company | IV |
| Eptifibatide (Integrilin) | 1998 | ACS, PCI | GP IIb/IIIa inhibitor | Millennium Pharma | IV |
| Tirofiban (Aggrastat) | 1998 | ACS, PCI | GP IIb/IIIa inhibitor | Medicure | IV |
| Avatrombopag (Mulpleta) | 2018 | Thrombocytopenia (CLD) | TPO receptor agonist | Dova Pharma | Oral |
| Lusutrombopag (Mulpleta) | 2015 (Japan) | Thrombocytopenia (CLD) | TPO receptor agonist | Shionogi | Oral |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Eptifibatide (Integrilin) | 1998 | ACS | GP IIb/IIIa inhibitor | Millennium | IV |
| Desmopressin (Stimate) | 2000 | Hemophilia A, vWD | FVIII/vWF release | Various | Intranasal |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Oritavancin (Orbactiv) | 2014 | ABSSSI | Lipoglycopeptide (cell wall) | Melinta Therapeutics | IV |
| Dalbavancin (Dalvance) | 2014 | ABSSSI | Lipoglycopeptide (cell wall) | Allergan | IV |
| Telavancin (Vibativ) | 2009 | HAP/VAP | Lipoglycopeptide (cell wall) | Theravance | IV |
| Daptomycin (Cubicin) | 2003 | ABSSSI, bacteremia | Lipopeptide (membrane) | Cubist Pharma | IV |
| Colistin (Coly-Mycin) | 1970 | MDR Gram-negative | Polypeptide (membrane) | Various | IV, inhaled |
| Polymyxin B (Aerosporin) | 1964 | MDR Gram-negative | Polypeptide (membrane) | Various | IV |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Ziconotide (Prialt) | 2004 | Severe chronic pain | N-type Ca²⁺ channel blocker | Jazz Pharma | Intrathecal |
| Botulinum toxin A (Botox) | 1989 | Dystonia, spasticity, chronic migraine | SNARE cleavage (ACh release) | Allergan | IM |
| Botulinum toxin B (Myobloc) | 2000 | Cervical dystonia | SNARE cleavage (ACh release) | Solstice Pharma | IM |
| Erenumab (Aimovig) | 2018 | Migraine prevention | CGRP receptor mAb | Amgen/Novartis | SC monthly |
| Fremanezumab (Ajovy) | 2018 | Migraine prevention | CGRP mAb | Teva | SC monthly/quarterly |
| Galcanezumab (Emgality) | 2018 | Migraine prevention | CGRP mAb | Eli Lilly | SC monthly |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Sermorelin (Geref) | 1990 | GHD (diagnostic) | GHRH analog | Serono | SC |
| Tesamorelin (Egrifta) | 2010 | HIV lipodystrophy | GHRH analog | Theratechnologies | SC |
| Somapacitan (Sogroya) | 2020 | GHD (adult) | GH receptor agonist (albumin-binding) | Novo Nordisk | SC weekly |
| Lonapegsomatropin (Skytrofa) | 2020 | GHD (pediatric) | GH prodrug (PEGSOMA) | Ascendis Pharma | SC weekly |
| RhGH (Genotropin, Norditropin, etc.) | 1985 | GHD, Turner’s | Recombinant GH | Various | SC |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Thymalfasin (Zadaxin) | 2001 (US) | HBV, vaccine adjuvant | Thymosin α1 analog | SciClone | SC |
| Glatiramer acetate (Copaxone) | 1996 | MS | Myelin basic protein analog | Teva | SC, IM |
| Bacillus Calmette-Guérin (BCG) | 1990 | Bladder cancer | Immune stimulant | Various | Intravesical |
| Drug | Approval Year | Indication | Mechanism | Sponsor | Route |
|---|
| Caspofungin (Cancidas) | 2001 | Invasive candidiasis | Echinocandin (cell wall) | Merck | IV |
| Micafungin (Mycamine) | 2005 | Invasive candidiasis | Echinocandin (cell wall) | Astellas | IV |
| Anidulafungin (Eraxis) | 2006 | Invasive candidiasis | Echinocandin (cell wall) | Pfizer | IV |
| Vasopressin (Pitressin) | 1950 | GI bleeding, vasodilatory shock | V1aR agonist | Various | IV |
| Octreotide (Sandostatin LAR) | 1998 | Acromegaly, NETs | Somatostatin analog (depot) | Novartis | IM monthly |
| Pasireotide (Signifor LAR) | 2014 | Cushing’s disease | Somatostatin analog (depot) | Novartis | IM monthly |
| Liraglutide (Saxenda) | 2014 | Obesity | GLP-1R agonist (higher dose) | Novo Nordisk | SC daily |
| Naltrexone/Bupropion (Contrave) | 2014 | Obesity | Opioid/GABA modulator | Orexigen | Oral (combination) |
| Lorcaserin (Belviq) | 2012 (withdrawn 2020) | Obesity | 5-HT2c agonist | Eisai | Oral |
| Phentermine/Topiramate (Qsymia) | 2012 | Obesity | Monoamine/GABA modulator | Vivus | Oral |
| Route | Description |
|---|
| SC | Subcutaneous |
| IM | Intramuscular |
| IV | Intravenous |
| PO | Per os (oral) |
| ICI | Intracavernous injection |
| Intranasal | Nasal administration |
| Intrathecal | Cerebrospinal fluid |
| Intravesical | Bladder instillation |
| Urethral | Transurethral |
| Implant | Subcutaneous implant |
